Biotechnology

Medison Pharma Announces Multi-Regional Partnership Agreement with argenx to Commercialize Efgartigimod Across Europe and Israel

PETACH TIKVAH, Israel, June 6, 2022 /PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today an exclusive multi-regional agreement withargenx...

2022-06-06 19:00 1984

NeuroAiD has shown favourable outcome in patients suffering from spinal cord injuries

* SATURN study aimed at assessing the safety and effects of a 6-month course of NeuroAiD (MLC601/MLC901) to augment functional and motor recovery after severe spinal cord injury (SCI). * NeuroAiD was safe as add-on treatment in patients with severe SCI. * One third of patients improved on AS...

2022-06-06 18:07 1770

CPHI China opens for international partnering after China rises in CPHI Index

The CPHI China Hosted Buyer Programme is empowering new partnering in China SHANGHAI, June 6, 2022 /PRNewswire/ -- CPHI & P-MEC China  opens its online international partnering platform as pharmaceutical and biopharmaceutical industries in the country report stron...

2022-06-06 16:51 4615

CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer

* The National Medical Products Administration approved sugemalimab for the treatment of patients with unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy * Sugemalimab became the first anti-PD-...

2022-06-06 13:15 2791

CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer

* The National Medical Products Administration approved sugemalimab for the treatment of patients with unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy * Sugemalimab became the first anti-PD-...

2022-06-06 12:23 2255

GILEAD SCIENCES APPOINTS DUSTIN HAINES AS NEW LEADER FOR ASIA 5 REGION

-- Mr Haines Brings a Strong Track Record of Global Commercial Successes and Corporate Leadership with a Career that Spans 20 Years in Pharmaceuticals -- -- He Joins Gilead's Asia 5 Team as the Company Celebrates 10 Years of Presence inAsia -- HONG KONG, June 6, 2022 /PRNewswire/ -- Gilead Scien...

2022-06-06 11:00 3819

OriCiro Announces Series B2 Financing to Advance Cell-Free DNA Technology for Innovative Therapeutics and Synthetic Biology

TOKYO, June 5, 2022 /PRNewswire/ -- OriCiro Genomics, a pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapy and synthetic biology, today announced that it has closed Series B2 financing from Asahi Kasei Medical Co., Ltd. OriCiro has advanced its busine...

2022-06-06 10:09 1816

Research Updates on KN046 Presented at 2022 ASCO

SUZHOU, China, June 6, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that research updates from four clinical studies of KN046 (PD-L1/CTLA-4 bispecific antibody) presented as a poster or published online at the 2022 American Society of Clinical Oncology Annual Meeting (20...

2022-06-06 09:47 2766

WuXi Biologics Launches First Commercial Drug Product Facility for Pre-Filled Syringes

* WuXi Biologics offers global partners high-efficiency and high-quality manufacturing services for clinical trial and commercial supply by increasing pre-filled syringes (PFS) capacity to 17 million units per year. * WuXi Biologics has established a global manufacturing network with 9 drug p...

2022-06-06 08:30 3655

JW Therapeutics Presents Latest Data of Carteyva® at 2022 ASCO Annual Meeting

SHANGHAI, June 5, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, presented the latest data of three clinical studies on Carteyva® (relmacabtagene autoleuce...

2022-06-05 18:30 4178

Gracell Biotechnologies Schedules Clinical Update Call After EHA2022

SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, June. 3, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today a...

2022-06-03 23:00 6351

KAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCE

SYDNEY, June 3, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce final data from its phase II study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298). The data is the subj...

2022-06-03 19:00 8709

Sanyou Super-Trillion Innovative Antibody Drug Discovery Platform Announced - World Premiere

SHANGHAI, June 2, 2022 /PRNewswire/ -- Sanyou Biopharmaceuticals officially launched STAL (Super-Trillion Antibody Libraries) onJune 3, 2022, which is a super-trillion innovative antibody drug discovery platform of Sanyou's own intellectual property.

2022-06-03 08:00 2428

IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma

SHANGHAI, NANJING, China, and SAN JOSE , Calif., June 2, 2022 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, and Innovent Biologics, Inc. ("Innoven...

2022-06-02 20:08 3336

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy

Multiple System Atrophy is a rare, rapidly progressive, neurodegenerative disease that causes profound disability MELBOURNE, Australia, June 2, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disea...

2022-06-02 20:00 2421

ProfoundBio Announces Completion of $70 Million Series A+ Financing to Advance Antibody-Drug Conjugate (ADC) Programs into the Clinic

- Advance PRO1184 and PRO1160 into clinical trials - Accelerate multiple programs into preclinical development and further strengthen/expand innovative technology platforms - Build vertically integrated internal capabilities for more efficient drug development WOODINVILLE, Wash. and SUZHOU, China...

2022-06-02 20:00 2585

Vazyme Releases 2021 Annual Report: Announces More Efforts in Technology innovation and Together with Partners for a Better Future

NANJING, China, June 2, 2022 /PRNewswire/ -- Vazyme, China's leading biotechnology company, has recently released its 2021 annual report, revealing that the company has maintained a steady and solid growth throughout the past year. The report shows that it has achieved$289 million in operating in...

2022-06-02 12:54 3203

Transcenta Releases Phase I Clinical Data of TST001 in Combination with CAPOX as the First Line Treatment of Advanced and Metastatic G/GEJ Cancer at ASCO 2022

SUZHOU, China, June 2, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that clinical data for...

2022-06-02 08:08 2792

Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOT BIOPHARM Shares

SUZHOU, China, June 2, 2022 /PRNewswire/ -- On June 1, 2022, TOT BIOPHARM International Company Limited (TOT BIOPHARM, Stock code: 1875.HK) announced that the company entered into a Share Subscription Agreement with VIVO Suzhou Fund and Centerlab. Pursuant to the agreement, Vivo Suzhou Fund and C...

2022-06-02 08:00 5917

Standigm Signs MOU with Merck Korea for AI drug Discovery Research

- Merck's retrosynthesis AI software SYNTHIA™ accelerates Standigm's synthesis capability SEOUL, South Korea, June 1, 2022 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, today announced the signing of a Memorandum of Und...

2022-06-01 21:00 2332
1 ... 171172173174175176177 ... 307